Study wrapper · #1191
EQ-5D Health Utility Gains with Once-Weekly Semaglutide 2.4 mg in People with MASH and F2/F3 Fibrosis: An Analysis of ESSENCE.
Editor's note
A small absolute gain, and the purpose of the analysis is economic rather than clinical: it supplies the utility inputs health-technology assessors need for cost-effectiveness models. The authors are appropriately cautious, since utilities were mapped from SF-36 scores rather than measured directly, using a UK tariff. Useful as supporting quality-of-life evidence in the semaglutide-MASH file rather than a headline efficacy finding.
Plain-language abstract
In this exploratory analysis of the phase 3 ESSENCE trial, 800 adults with biopsy-confirmed MASH and moderate-to-advanced liver fibrosis received either once-weekly semaglutide 2.4 mg or placebo for 72 weeks. Quality-of-life scores, converted into the standard health-utility value payers use, improved modestly but significantly in the semaglutide group - a difference of 0.03 on a scale where both groups started near 0.78. The effect was consistent across both fibrosis stages.